Date: 2022-01-10

Type of information: Plant acquisition

Compound: solid dose manufacturing site at Fontaine-lès-Dijon (France)

Company: Recipharm (Sweden) Astrea Pharma (France)

Therapeutic area: Technology - Services

Type agreement:

Action mechanism:



Recipharm announced the sale to Astrea Pharma, a newly established CDMO provider focused on small molecule oral solid and aseptic dosages, of the solid dose manufacturing site at Fontaine-lès-Dijon, France.  Under Recipharm’s ownership, Fontaine has developed extensive experience manufacturing and packaging tablets and capsules. The capabilities fit well with Astrea’s ambitions to grow a broad range of different processing, filling and packaging technologies, as well as a wide geographical reach. Astrea’s owners are seasoned veterans in the CDMO industry and have the financial backing of the French long-term investment company Groupe Chevrillon, a family-owned business with a strong track record of investment in industrial and service companies.

Financial terms:

Latest news:

Is general: Yes